[CAS NO. 246529-22-6] Icomidocholicacid

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [246529-22-6]

Catalog

HY-19796

Brand

MCE

CAS

246529-22-6

DESCRIPTION [246529-22-6]

Overview

MDL	-
Molecular Weight	702.10
Molecular Formula	C44H79NO5
SMILES	C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@@H](NC(CCCCCCCCCCCCCCCCCCC)=O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C

For research use only. We do not sell to patients.

Summary

Icomidocholic acid (Aramchol) is a conjugate of cholic acid and arachidic acid that could inhibit stearoyl coenzyme A desaturase 1 (SCD1) activity. Icomidocholic acid has potential use in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) treatment ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02325492	Galmed Pharmaceuticals Ltd	Gallstones	October 2014	Phase 2
NCT02279524	Galmed Research and Development, Ltd.\|Sharp Clinical Services\|Diamond Pharma Services Regulatory Affairs Consultancy\|Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico\|ClinIntel\|Itamar-Medical, Israel\|One Way Liver OWL\|Medical University of Graz\|Tel-Aviv Sourasky Medical Center\|DSG EDC\|TransPerfect\|Clinical Reference Laboratory\|Galmed Pharmaceuticals Ltd	Fatty Liver\|Non-Alcoholic Steatohepatitis\|Liver Diseases\|Liver Fibroses	April 29, 2015	Phase 2
NCT02374437	Galmed Pharmaceuticals Ltd	Healthy Volunteers	April 2014	Phase 1
NCT01094158	Galmed Medical Reserch\|Tel-Aviv Sourasky Medical Center\|Beilinson Hospital, Petach Tikva,Israel\|Meir Medical Center\|Kaplan Hospital ,Rehovot,Israel\|Soroka Hospital,Beer Sheva,Israel\|Hadassah Medical Organization\|Hillel Yaffe Medical Center\|Rambam Hospital, Haifa, Israel\|The Lady Davis Carmel Medical Center\|Holy Family Hospital, Nazareth, Israel\|Ziv Hospital	Non-Alcoholic Fatty Liver Disease\|Nonalcoholic Steatohepatitis\|Metabolic Syndrome	November 2010	Phase 2
NCT03774173	Galmed Pharmaceuticals Ltd\|Hammersmith Medicines Research\|Analyst Research Laboratories\|Diamond Pharma Services Regulatory Affairs Consultancy	Healthy	December 8, 2018	Phase 1
NCT04104321	Galmed Research and Development, Ltd.\|Galmed Pharmaceuticals Ltd	Nonalcoholic Steatohepatitis (NASH)	September 23, 2019	Phase 3
NCT02803996	Galmed Pharmaceuticals Ltd\|WCCT Global\|Alpha IRB\|Analyst Research Laboratories\|Kramer Consulting, LLC\|Diamond Pharma Services Regulatory Affairs Consultancy	Healthy Volunteers	May 2016	Phase 1
NCT04480827	Galmed Research and Development, Ltd.\|Galmed Pharmaceuticals Ltd	Hepatic Impairment	January 22, 2020	Phase 1
NCT02684591	University of California, San Diego	Nonalcoholic Fatty Liver Disease\|HIV	January 2016	Phase 2
NCT00776841	Galmed Medical Reserch	Healthy	September 2008	Phase 1
NCT03760848	Galmed Pharmaceuticals Ltd\|Hammersmith Medicines Research\|Analyst Research Laboratories\|Alderley Analytical\|Diamond Pharma Services Regulatory Affairs Consultancy	Healthy	November 12, 2018	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 35.61 mM ; Need ultrasonic)

H ₂ O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.4243 mL	7.1215 mL	14.2430 mL
5 mM	0.2849 mL	1.4243 mL	2.8486 mL
10 mM	0.1424 mL	0.7121 mL	1.4243 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (2.96 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (2.96 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Cholan-24-oic acid, 7,12-dihydroxy-3-[(1-oxoeicosyl)amino]-, (3β,5β,7α,12α)-

(3β,5β,7α,12α)-7,12-Dihydroxy-3-[(1-oxoeicosyl)amino]cholan-24-oic acid

Aramchol

C₂₀-FABAC

(3β)-Arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid